GlassScriptPhysician profile
Anna C Mcgrain
NPI 1164472395
$6,904.11
in general payments reported to CMS, 2019-2025
30 companies · $1,393 in 2025
The $1,393 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,147 · 2022: $1,385 · 2023: $1,075 · 2024: $1,904 · 2025: $1,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,987 · Consulting Fee: $285 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,987.18 |
| Consulting Fee | $285.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $1,469.44 | 2023-2025 | Jelmyto |
| Janssen Biotech, INC. | $1,356.44 | 2021-2025 | Erleada, Akeega, Carvykti |
| Dendreon Pharmaceuticals LLC | $611.95 | 2021-2025 | Provenge |
| Teleflex LLC | $555.41 | 2021-2023 | Urolift |
| Ferring Pharmaceuticals INC. | $496.86 | 2024-2025 | Adstiladrin |
| Merck Sharp & Dohme LLC | $490.66 | 2022-2025 | Keytruda, Lynparza |
| Axonics, INC. | $441.09 | 2021-2024 | Axonics |
| Boston Scientific Corporation | $221.78 | 2021-2024 | Rezum Generator |
| Palette Life Sciences, INC. | $178.31 | 2022 | |
| Myovant Sciences INC. | $169.83 | 2021-2022 | |
| Pfizer INC. | $140.36 | 2024-2025 | |
| Immunitybio, INC. | $113.63 | 2025 | |
| Endo Pharmaceuticals INC. | $95.92 | 2022-2024 | Xiaflex, Aveed, Edex |
| Bayer Healthcare Pharmaceuticals INC. | $78.42 | 2022-2024 | |
| Procept Biorobotics Corporation | $74.45 | 2024 | Aquabeam System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $63.54 | 2021-2025 | |
| Antares Pharma, INC. | $50.27 | 2022-2025 | Xyosted |
| Tolmar, INC. | $49.90 | 2024-2025 | Eligard, Jatenzo |
| Sumitomo Pharma America, INC. | $49.06 | 2023-2025 | Orgovyx, Gemtesa |
| Progenics Pharmaceuticals, INC. | $35.43 | 2023-2025 | Pylarify |
| Accord Healthcare, INC. | $27.40 | 2025 | |
| 180 Medical, INC. | $18.82 | 2021 | |
| Astellas Pharma US INC | $16.47 | 2021 | |
| Rochester Medical Corporation | $16.47 | 2021 | |
| Amgen INC. | $14.64 | 2022 | |
| Endo USA, INC. | $14.24 | 2025 | Xiaflex |
| Novartis Pharmaceuticals Corporation | $13.98 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $13.40 | 2021 | |
| Sun Pharmaceutical Industries INC. | $13.33 | 2024 | |
| Urovant Sciences INC | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Mcgrain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.